Evidence Map v1

See the shape of every peptide record

Compare selected trials, PubMed bibliography, regulatory records, source-year reach, structured detail, and known collection gaps across all 41 canonical profiles.

Canonical profiles

41 deterministic maps

Open the research atlas →

2017–2026 selected source window

Abaloparatide

60 dated records3/4 lanes present10 source years
  • Trials 9 2 with phase · 2 with status
  • Trial-publication graph 3 exact source-declared NCT ↔ PMID links
  • PubMed 33 9 with bibliography
  • Drugs@FDA 1 exact reviewed application connections
  • FDA history 11 dated AP submissions · 23 official documents
  • DailyMed 16 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

2009–2026 selected source window

Afamelanotide

55 dated records3/4 lanes present12 source years
  • Trials 16 2 with phase · 2 with status
  • Trial-publication graph 3 exact source-declared NCT ↔ PMID links
  • PubMed 25 5 with bibliography
  • Drugs@FDA 1 exact reviewed application connections
  • FDA history 2 dated AP submissions · 5 official documents
  • DailyMed 11 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

2025 selected source window

Amycretin

3 dated records1/4 lanes present1 source years
  • Trials 0 0 with phase · 0 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 3 0 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Clinical trials, Regulatory, Safety.

Open the full map →

2017–2026 selected source window

BPC-157

50 dated records3/4 lanes present7 source years
  • Trials 1 0 with phase · 0 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 47 22 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

2011–2026 selected source window

Bremelanotide

29 dated records3/4 lanes present13 source years
  • Trials 4 1 with phase · 1 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 21 5 with bibliography
  • Drugs@FDA 1 exact reviewed application connections
  • FDA history 2 dated AP submissions · 5 official documents
  • DailyMed 1 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

2022–2026 selected source window

Cagrilintide

12 dated records2/4 lanes present4 source years
  • Trials 6 2 with phase · 2 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 6 0 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Regulatory, Safety.

Open the full map →

2010–2025 selected source window

CJC-1295

9 dated records2/4 lanes present7 source years
  • Trials 0 0 with phase · 0 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 8 0 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Clinical trials, Safety.

Open the full map →

2014–2026 selected source window

Dulaglutide

89 dated records4/4 lanes present13 source years
  • Trials 8 2 with phase · 3 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 38 14 with bibliography
  • Drugs@FDA 1 exact reviewed application connections
  • FDA history 22 dated AP submissions · 42 official documents
  • DailyMed 39 exact SPL version receipts

All four selected record lanes are represented.

Open the full map →

2013–2026 selected source window

Elamipretide

47 dated records3/4 lanes present8 source years
  • Trials 7 2 with phase · 2 with status
  • Trial-publication graph 1 exact source-declared NCT ↔ PMID links
  • PubMed 38 14 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

2003–2026 selected source window

Emideltide

44 dated records2/4 lanes present13 source years
  • Trials 0 0 with phase · 0 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 42 17 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Clinical trials, Safety.

Open the full map →

2012–2026 selected source window

Epitalon

25 dated records2/4 lanes present6 source years
  • Trials 0 0 with phase · 0 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 23 0 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Clinical trials, Safety.

Open the full map →

2005–2026 selected source window

Exenatide

116 dated records3/4 lanes present20 source years
  • Trials 48 1 with phase · 2 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 48 24 with bibliography
  • Drugs@FDA 5 exact reviewed application connections
  • FDA history 87 dated AP submissions · 152 official documents
  • DailyMed 5 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

2015–2026 selected source window

GHK-Cu

16 dated records1/4 lanes present7 source years
  • Trials 0 0 with phase · 0 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 16 4 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Clinical trials, Regulatory, Safety.

Open the full map →

1960–2026 selected source window

Glucagon

299 dated records4/4 lanes present23 source years
  • Trials 29 2 with phase · 2 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 241 122 with bibliography
  • Drugs@FDA 10 exact reviewed application connections
  • FDA history 92 dated AP submissions · 72 official documents
  • DailyMed 2 exact SPL version receipts

All four selected record lanes are represented.

Open the full map →

2026 selected source window

Insulin glargine-aldy

4 dated records1/4 lanes present1 source years
  • Trials 0 0 with phase · 0 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 0 0 with bibliography
  • Drugs@FDA 1 exact reviewed application connections
  • FDA history 1 dated AP submissions · 2 official documents
  • DailyMed 3 exact SPL version receipts

Missing selected lanes: Clinical trials, Literature metadata, Safety.

Open the full map →

2012–2026 selected source window

Ipamorelin

17 dated records3/4 lanes present7 source years
  • Trials 2 0 with phase · 0 with status
  • Trial-publication graph 1 exact source-declared NCT ↔ PMID links
  • PubMed 14 1 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

2003–2026 selected source window

KPV

13 dated records2/4 lanes present7 source years
  • Trials 0 0 with phase · 0 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 11 0 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Clinical trials, Safety.

Open the full map →

2007–2026 selected source window

Lanreotide

68 dated records4/4 lanes present14 source years
  • Trials 12 1 with phase · 1 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 45 21 with bibliography
  • Drugs@FDA 3 exact reviewed application connections
  • FDA history 24 dated AP submissions · 39 official documents
  • DailyMed 3 exact SPL version receipts

All four selected record lanes are represented.

Open the full map →

1985–2026 selected source window

Leuprolide

212 dated records4/4 lanes present32 source years
  • Trials 112 45 with phase · 46 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 46 22 with bibliography
  • Drugs@FDA 24 exact reviewed application connections
  • FDA history 424 dated AP submissions · 450 official documents
  • DailyMed 6 exact SPL version receipts

All four selected record lanes are represented.

Open the full map →

2012–2026 selected source window

Linaclotide

97 dated records4/4 lanes present15 source years
  • Trials 13 3 with phase · 3 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 48 24 with bibliography
  • Drugs@FDA 3 exact reviewed application connections
  • FDA history 25 dated AP submissions · 34 official documents
  • DailyMed 28 exact SPL version receipts

All four selected record lanes are represented.

Open the full map →

2009–2026 selected source window

Liraglutide

164 dated records4/4 lanes present17 source years
  • Trials 77 13 with phase · 14 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 54 25 with bibliography
  • Drugs@FDA 13 exact reviewed application connections
  • FDA history 61 dated AP submissions · 94 official documents
  • DailyMed 2 exact SPL version receipts

All four selected record lanes are represented.

Open the full map →

2015–2026 selected source window

Lixisenatide

63 dated records3/4 lanes present12 source years
  • Trials 5 1 with phase · 1 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 34 14 with bibliography
  • Drugs@FDA 1 exact reviewed application connections
  • FDA history 7 dated AP submissions · 16 official documents
  • DailyMed 20 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

2025–2026 selected source window

Maridebart cafraglutide

14 dated records2/4 lanes present2 source years
  • Trials 10 4 with phase · 4 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 4 1 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Regulatory, Safety.

Open the full map →

2024–2026 selected source window

Mazdutide

13 dated records2/4 lanes present3 source years
  • Trials 8 4 with phase · 4 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 5 0 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Regulatory, Safety.

Open the full map →

2020–2026 selected source window

MOTS-c

43 dated records2/4 lanes present6 source years
  • Trials 0 0 with phase · 0 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 41 17 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Clinical trials, Safety.

Open the full map →

1988–2026 selected source window

Octreotide

157 dated records4/4 lanes present25 source years
  • Trials 56 3 with phase · 3 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 57 30 with bibliography
  • Drugs@FDA 27 exact reviewed application connections
  • FDA history 180 dated AP submissions · 72 official documents
  • DailyMed 2 exact SPL version receipts

All four selected record lanes are represented.

Open the full map →

2026 selected source window

Pemvidutide

4 dated records1/4 lanes present1 source years
  • Trials 4 2 with phase · 2 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 0 0 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Literature metadata, Regulatory, Safety.

Open the full map →

2026 selected source window

Petrelintide

6 dated records2/4 lanes present1 source years
  • Trials 5 3 with phase · 3 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 1 0 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Regulatory, Safety.

Open the full map →

2017–2026 selected source window

Plecanatide

44 dated records3/4 lanes present10 source years
  • Trials 10 2 with phase · 2 with status
  • Trial-publication graph 2 exact source-declared NCT ↔ PMID links
  • PubMed 16 2 with bibliography
  • Drugs@FDA 1 exact reviewed application connections
  • FDA history 6 dated AP submissions · 15 official documents
  • DailyMed 14 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

2001–2026 selected source window

Pramlintide

66 dated records3/4 lanes present15 source years
  • Trials 4 1 with phase · 1 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 48 24 with bibliography
  • Drugs@FDA 1 exact reviewed application connections
  • FDA history 11 dated AP submissions · 20 official documents
  • DailyMed 11 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

2024–2026 selected source window

Retatrutide

19 dated records3/4 lanes present3 source years
  • Trials 3 2 with phase · 2 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 15 5 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

2017–2026 selected source window

Semaglutide

232 dated records4/4 lanes present10 source years
  • Trials 96 24 with phase · 26 with status
  • Trial-publication graph 3 exact source-declared NCT ↔ PMID links
  • PubMed 94 38 with bibliography
  • Drugs@FDA 5 exact reviewed application connections
  • FDA history 50 dated AP submissions · 109 official documents
  • DailyMed 19 exact SPL version receipts

All four selected record lanes are represented.

Open the full map →

2006–2026 selected source window

Semax

42 dated records2/4 lanes present11 source years
  • Trials 0 0 with phase · 0 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 40 16 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Clinical trials, Safety.

Open the full map →

2020–2026 selected source window

Setmelanotide

64 dated records3/4 lanes present7 source years
  • Trials 12 3 with phase · 3 with status
  • Trial-publication graph 6 exact source-declared NCT ↔ PMID links
  • PubMed 37 14 with bibliography
  • Drugs@FDA 1 exact reviewed application connections
  • FDA history 6 dated AP submissions · 13 official documents
  • DailyMed 10 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

2025–2026 selected source window

Survodutide

10 dated records2/4 lanes present2 source years
  • Trials 7 4 with phase · 4 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 3 0 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Regulatory, Safety.

Open the full map →

2018–2026 selected source window

TB-500

7 dated records3/4 lanes present3 source years
  • Trials 1 1 with phase · 1 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 4 0 with bibliography
  • Drugs@FDA 0 exact reviewed application connections
  • FDA history 0 dated AP submissions · 0 official documents
  • DailyMed 0 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

1999–2026 selected source window

Teriparatide

146 dated records3/4 lanes present24 source years
  • Trials 71 7 with phase · 8 with status
  • Trial-publication graph 1 exact source-declared NCT ↔ PMID links
  • PubMed 55 28 with bibliography
  • Drugs@FDA 6 exact reviewed application connections
  • FDA history 38 dated AP submissions · 57 official documents
  • DailyMed 8 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

2010–2026 selected source window

Tesamorelin

44 dated records3/4 lanes present13 source years
  • Trials 10 1 with phase · 1 with status
  • Trial-publication graph 4 exact source-declared NCT ↔ PMID links
  • PubMed 21 1 with bibliography
  • Drugs@FDA 1 exact reviewed application connections
  • FDA history 12 dated AP submissions · 19 official documents
  • DailyMed 9 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

2022–2026 selected source window

Tirzepatide

165 dated records4/4 lanes present5 source years
  • Trials 65 17 with phase · 17 with status
  • Trial-publication graph 1 exact source-declared NCT ↔ PMID links
  • PubMed 65 23 with bibliography
  • Drugs@FDA 2 exact reviewed application connections
  • FDA history 24 dated AP submissions · 60 official documents
  • DailyMed 21 exact SPL version receipts

All four selected record lanes are represented.

Open the full map →

2021–2026 selected source window

Vosoritide

53 dated records3/4 lanes present6 source years
  • Trials 8 2 with phase · 2 with status
  • Trial-publication graph 2 exact source-declared NCT ↔ PMID links
  • PubMed 32 8 with bibliography
  • Drugs@FDA 1 exact reviewed application connections
  • FDA history 3 dated AP submissions · 8 official documents
  • DailyMed 7 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →

2004–2026 selected source window

Ziconotide

56 dated records3/4 lanes present13 source years
  • Trials 2 0 with phase · 1 with status
  • Trial-publication graph 0 exact source-declared NCT ↔ PMID links
  • PubMed 46 22 with bibliography
  • Drugs@FDA 1 exact reviewed application connections
  • FDA history 6 dated AP submissions · 10 official documents
  • DailyMed 6 exact SPL version receipts

Missing selected lanes: Safety.

Open the full map →